Response to ibrutinib in a patient with IgG lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation

Leuk Lymphoma. 2016 Nov;57(11):2699-701. doi: 10.3109/10428194.2016.1157875. Epub 2016 Mar 16.

Authors

Jorge J Castillo¹, Irene M Ghobrial¹, Steven P Treon¹

Affiliation

¹ a Division of Hematologic Malignancies , Dana-Farber Cancer Institute, Harvard Medical School , Boston , MA , USA.

PMID: 26980069
DOI: 10.3109/10428194.2016.1157875

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adenine / analogs & derivatives
Amino Acid Substitution
Female
Humans
Immunoglobulin G* / metabolism
Leucine / genetics
Mutation, Missense*
Myeloid Differentiation Factor 88 / genetics*
Piperidines
Proline / genetics
Pyrazoles / therapeutic use*
Pyrimidines / therapeutic use*
Treatment Outcome
Waldenstrom Macroglobulinemia / drug therapy*
Waldenstrom Macroglobulinemia / genetics
Waldenstrom Macroglobulinemia / immunology

Substances

Immunoglobulin G
MYD88 protein, human
Myeloid Differentiation Factor 88
Piperidines
Pyrazoles
Pyrimidines
ibrutinib
Proline
Leucine
Adenine